Literature DB >> 8592677

Proton-cotransport of pravastatin across intestinal brush-border membrane.

I Tamai1, H Takanaga, H Maeda, T Ogihara, M Yoneda, A Tsuji.   

Abstract

PURPOSE: The purpose of the present study is to clarify the intestinal brush-border transport mechanism of a weak organic acid, pravastatin, an HMG-CoA reductase inhibitor.
METHODS: The transport of pravastatin was studied by using intestinal brush-border membrane vesicles prepared from rabbit jejunum, and uptake by the membrane vesicles was measured using rapid filtration technique.
RESULTS: The initial uptake of [14C]pravastatin was markedly increased with decreases in extravesicular pH and showed a clear overshoot phenomenon in the presence of a proton gradient (pHin/out = 7.5/5.5). A protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, significantly reduced the uptake of [14C]pravastatin. In addition, an ionophore for sodium, potassium and proton, nigericin, stimulated the uptake of [14C]pravastatin in the presence of a potassium gradient ([K+]in/[K+]out = 0/145 mM). On the other hand, neither the imposition of an inwardly directed sodium gradient nor an outwardly directed bicarbonate gradient stimulated the uptake of [14C]pravastatin. In the presence of a proton gradient (pHin/out = 7.5/5.5), the initial uptake of pravastatin was saturable with the apparent Kt of 15.2 +/- 3.2 mM and Jmax of 10.6 +/- 1.21 nmol/mg protein/10 sec. The uptake of pravastatin was significantly inhibited by monocarboxylic acid compounds such as acetic acid and nicotinic acid in a competitive manner but not by di- or tricarboxylic acids, or acidic amino acid.
CONCLUSION: It was concluded that a pH-dependent transport of pravastatin across the brush-border membrane occurs by a proton-gradient dependent carrier-mediated mechanism rather than by simple diffusion of its unionized form.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592677     DOI: 10.1023/a:1016269806840

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  pH-dependent intestinal transport of monocarboxylic acids: carrier-mediated and H(+)-cotransport mechanism versus pH-partition hypothesis.

Authors:  A Tsuji; M T Simanjuntak; I Tamai; T Terasaki
Journal:  J Pharm Sci       Date:  1990-12       Impact factor: 3.534

2.  Participation of monocarboxylic anion and bicarbonate exchange system for the transport of acetic acid and monocarboxylic acid drugs in the small intestinal brush-border membrane vesicles.

Authors:  M T Simanjuntak; T Terasaki; I Tamai; A Tsuji
Journal:  J Pharmacobiodyn       Date:  1991-09

3.  Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  T Koga; Y Shimada; M Kuroda; Y Tsujita; K Hasegawa; M Yamazaki
Journal:  Biochim Biophys Acta       Date:  1990-07-16

4.  Carrier-mediated uptake of nicotinic acid by rat intestinal brush-border membrane vesicles and relation to monocarboxylic acid transport.

Authors:  M T Simanjuntak; I Tamai; T Terasaki; A Tsuji
Journal:  J Pharmacobiodyn       Date:  1990-05

5.  The physiological disposition of lovastatin.

Authors:  D E Duggan; I W Chen; W F Bayne; R A Halpin; C A Duncan; M S Schwartz; R J Stubbs; S Vickers
Journal:  Drug Metab Dispos       Date:  1989 Mar-Apr       Impact factor: 3.922

6.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

Authors:  M Yamazaki; H Suzuki; M Hanano; T Tokui; T Komai; Y Sugiyama
Journal:  Am J Physiol       Date:  1993-01

7.  Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys.

Authors:  T Komai; K Kawai; T Tokui; Y Tokui; C Kuroiwa; E Shigehara; M Tanaka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

8.  Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.

Authors:  A Tsuji; A Saheki; I Tamai; T Terasaki
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

9.  Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.

Authors:  S Vickers; C A Duncan; I W Chen; A Rosegay; D E Duggan
Journal:  Drug Metab Dispos       Date:  1990 Mar-Apr       Impact factor: 3.922

10.  H+ gradient-dependent and carrier-mediated transport of cefixime, a new cephalosporin antibiotic, across brush-border membrane vesicles from rat small intestine.

Authors:  A Tsuji; T Terasaki; I Tamai; H Hirooka
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

View more
  14 in total

Review 1.  Pharmacophore-based discovery of ligands for drug transporters.

Authors:  Cheng Chang; Sean Ekins; Praveen Bahadduri; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

Review 2.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

3.  Application of fractal kinetics for carrier-mediated transport of drugs across intestinal epithelial membrane.

Authors:  T Ogihara; I Tamai; A Tsuji
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter.

Authors:  H Yabuuchi; I Tamai; Y Sai; A Tsuji
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

5.  Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.

Authors:  T Tokui; D Nakai; R Nakagomi; H Yawo; T Abe; Y Sugiyama
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

6.  Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide.

Authors:  Yoshiyuki Shirasaka; Kensuke Suzuki; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2010-08-05       Impact factor: 4.200

7.  No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat.

Authors:  A Lindahl; S Frid; A L Ungell; H Lennernas
Journal:  AAPS PharmSci       Date:  2000

Review 8.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

9.  MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina.

Authors:  K Hosoya; T Kondo; M Tomi; H Takanaga; S Ohtsuki; T Terasaki
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

Review 10.  Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.

Authors:  Marilyn E Morris; Melanie A Felmlee
Journal:  AAPS J       Date:  2008-06-04       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.